Studies
Biomarkers of Blood Brain Barrier Injury in Methamphetamine Use and HIV
Agency: NIH
Agency Award Number: K23 DA037793
To provide focused training and mentoring in the neurobiological aspects of methamphetamine (METH) addiction and HIV disease by identifying and measuring a panel of biomarkers specific to blood brain barrier (BBB) injury and examining the role of BBB dysfunction in METH- and HIV-associated neurocognitive impairment and functional decline. Such research bridging laboratory neurobiological discoveries with their clinical expression and real-world impact among persons living with METH addiction and HIV disease may provide valuable insight into the development of more effective pharmacological treatments and improve overall quality of life.